Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Insider Trading Activity – CEO Sold 49,456 shares of Stock

0

Insider Trading Activity For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

John Maraganore , CEO of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reportedly Sold 49,456 shares of the company’s stock at an average price of 79.45 for a total transaction amount of $3,929,279.20 SEC Form

Insider Trading History For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

  • On 1/22/2013 Philip A Sharp, Director, bought 4,967 with an average share price of $20.13 per share and the total transaction amounting to $99,985.71.
  • On 3/26/2013 Kevin P Starr, Director, sold 52,631 with an average share price of $23.49 per share and the total transaction amounting to $1,236,302.19.
  • On 5/28/2013 Laurence Reid, SVP, sold 5,000 with an average share price of $30.00 per share and the total transaction amounting to $150,000.00.
  • On 5/28/2013 Barry E Greene, COO, sold 22,822 with an average share price of $30.00 per share and the total transaction amounting to $684,660.00.
  • On 6/11/2013 Akshay Vaishnaw, EVP, sold 15,000 with an average share price of $31.08 per share and the total transaction amounting to $466,200.00.
  • On 6/17/2013 Michael Mason, VP, sold 23,625 with an average share price of $29.93 per share and the total transaction amounting to $707,096.25.
  • On 7/1/2013 Michael Mason, VP, sold 27,000 with an average share price of $32.00 per share and the total transaction amounting to $864,000.00.
  • Analyst Ratings History For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

    • On 10/30/2017 FBR & Co Initiated Coverage of rating Buy to Buy with a price target of $150.00
    • On 11/9/2017 JPMorgan Chase & Co. Upgraded rating Neutral to Overweight
    • On 3/13/2018 Credit Suisse Group Boost Price Target of rating Outperform to Outperform with a price target of $151.00 to $154.00
    • On 8/6/2018 Jefferies Financial Group Reiterated Rating Buy with a price target of $149.00
    • On 8/13/2018 B. Riley Boost Price Target of rating Buy to Buy with a price target of $210.00 to $230.00
    • On 8/28/2018 JMP Securities Set Price Target of rating Buy with a price target of $198.00
    • On 12/17/2018 Guggenheim Initiated Coverage of rating Buy with a price target of $105.00

    Recent Trading Activity for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
    Shares of Alnylam Pharmaceuticals, Inc. closed the previous trading session at with 80.39 shares trading hands.